Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Sol-Gel Technologies Ltd (NQ: SLGL )

0.8210 -0.0429 (-4.97%)
Streaming Delayed Price Updated: 3:55 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,634
Open 0.8790
Bid (Size) 0.6720 (10)
Ask (Size) 0.8700 (3)
Prev. Close 0.8639
Today's Range 0.8146 - 0.8790
52wk Range 0.6311 - 4.050
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SLGL Stock Earnings: Sol-Gel Technologies Misses EPS, Misses Revenue for Q1 2024
SLGL stock results show that Sol-Gel Technologies missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Week in Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
In the headline deal, Takeda acquires global rights from AC Immune of Switzerland for $100 million upfront and up to $2.1B in milestones. 
Via Talk Markets

Performance

YTD
-32.71%
-32.71%
1 Month
-10.58%
-10.58%
3 Month
-12.66%
-12.66%
6 Month
-28.89%
-28.89%
1 Year
-77.87%
-77.87%

More News

Read More
Sol-Gel Technologies: Q4 Earnings Insights
Via Benzinga
Recap: Sol-Gel Technologies Q3 Earnings
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Expert Ratings for Sol-Gel Technologies
Via Benzinga
Sol-Gel Technologies: Q1 Earnings Insights
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) Making Surprising Moves in Wednesday Session
Via Investor Brand Network
7 Biotech Stocks That Could Be the Next Big Thing
Via InvestorPlace
Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
The Top 7 Penny Stocks to Invest in for the Long-Term
Via InvestorPlace
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
Via Benzinga
What Does Sunshine Biopharma's Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market?
Via Benzinga
Nasdaq Turns Higher; Applied Genetic Technologies Shares Surge
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022
Via Benzinga
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday
Via Benzinga
Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
Via Benzinga
Earnings Scheduled For August 4, 2021
Via Benzinga
Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris
Via Benzinga
Exposures Product Safety
Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States
From Galderma
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.